Michael von Bergwelt‐Baildon

13.5k total citations · 4 hit papers
214 papers, 6.3k citations indexed

About

Michael von Bergwelt‐Baildon is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Michael von Bergwelt‐Baildon has authored 214 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 69 papers in Immunology and 35 papers in Epidemiology. Recurrent topics in Michael von Bergwelt‐Baildon's work include CAR-T cell therapy research (66 papers), Immunotherapy and Immune Responses (41 papers) and Cancer Immunotherapy and Biomarkers (39 papers). Michael von Bergwelt‐Baildon is often cited by papers focused on CAR-T cell therapy research (66 papers), Immunotherapy and Immune Responses (41 papers) and Cancer Immunotherapy and Biomarkers (39 papers). Michael von Bergwelt‐Baildon collaborates with scholars based in Germany, United States and Switzerland. Michael von Bergwelt‐Baildon's co-authors include Alexander Shimabukuro‐Vornhagen, Sebastian Theurich, Sebastian Kobold, Stefan Endres, Marion Subklewe, Tobias Herold, Vindi Jurinović, Johannes C. Hellmuth, Brian J. Lipworth and Tobias Weinberger and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Circulation and Nature Medicine.

In The Last Decade

Michael von Bergwelt‐Baildon

189 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

2020 687 citations Tobias Herold, Vindi Jurinović et al. profile →
Advances in cancer immunotherapy 2019 – latest trends

2019 400 citations Stephan Krüger, Sebastian Kobold et al. profile →
Teaching an old dog new tricks: next-generation CAR T cells

2018 329 citations Stefan Endres, Michael von Bergwelt‐Baildon et al. profile →
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy

2024 99 citations David M. Cordas dos Santos, Sebastian Theurich et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael von Bergwelt‐Baildon Germany	41	3.4k	2.3k	1.1k	808	717	214	6.3k
Vito Racanelli Italy	47	1.6k 0.5×	2.0k 0.9×	1.7k 1.6×	413 0.5×	590 0.8×	151	6.5k
Martin D. McCarter United States	53	2.8k 0.8×	2.2k 1.0×	1.5k 1.4×	497 0.6×	2.3k 3.2×	230	8.4k
Nicola Silvestris Italy	50	3.7k 1.1×	1.3k 0.6×	2.4k 2.2×	230 0.3×	1.5k 2.1×	319	7.4k
Andrew M. Evens United States	49	3.5k 1.0×	1.1k 0.5×	1.3k 1.2×	607 0.8×	916 1.3×	305	7.8k
Depei Wu China	38	2.0k 0.6×	1.5k 0.7×	1.7k 1.6×	463 0.6×	281 0.4×	512	6.5k
Irit Avivi Israel	40	2.0k 0.6×	740 0.3×	919 0.9×	480 0.6×	400 0.6×	247	4.6k
Bernard Bonnotte France	42	1.6k 0.5×	2.8k 1.2×	1.3k 1.2×	261 0.3×	1.0k 1.4×	202	6.3k
Franco Silvestris Italy	41	2.5k 0.7×	1.8k 0.8×	2.6k 2.4×	161 0.2×	630 0.9×	216	7.5k
Maria De Santis Italy	46	2.5k 0.7×	888 0.4×	1.8k 1.7×	701 0.9×	2.2k 3.1×	217	10.2k
Yi‐Bin Chen United States	35	1.5k 0.4×	1.1k 0.5×	1.1k 1.0×	683 0.8×	213 0.3×	197	4.9k

Countries citing papers authored by Michael von Bergwelt‐Baildon

Since Specialization

Citations

This map shows the geographic impact of Michael von Bergwelt‐Baildon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael von Bergwelt‐Baildon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael von Bergwelt‐Baildon more than expected).

Fields of papers citing papers by Michael von Bergwelt‐Baildon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael von Bergwelt‐Baildon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael von Bergwelt‐Baildon. The network helps show where Michael von Bergwelt‐Baildon may publish in the future.

Co-authorship network of co-authors of Michael von Bergwelt‐Baildon

This figure shows the co-authorship network connecting the top 25 collaborators of Michael von Bergwelt‐Baildon. A scholar is included among the top collaborators of Michael von Bergwelt‐Baildon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael von Bergwelt‐Baildon. Michael von Bergwelt‐Baildon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jurinović, Vindi, S. Abdel-Rahman, Markus Albertsmeier, et al.. (2025). Doxorubicin Plus Dacarbazine Versus Doxorubicin Plus Ifosfamide in Combination With Regional Hyperthermia in Patients With Advanced Leiomyosarcoma: A Propensity Score‐Matched Analysis. Cancer Medicine. 14(4). e70655–e70655. 3 indexed citations

Mellinghoff, Sibylle C., Martin Thelen, Michael von Bergwelt‐Baildon, et al.. (2025). Immune Phenotypes in Patients With Invasive Mould Infection Support the Use of PD‐1 Inhibition as Potential Treatment Option. Mycoses. 68(3). e70044–e70044. 2 indexed citations

Berger, Karin, et al.. (2025). Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany. Annals of Hematology. 104(9). 4625–4635.

Gioia, Dorit Di, Vindi Jurinović, Stefanie Corradini, et al.. (2025). Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich. Cardio-Oncology. 11(1). 58–58.

Stock, Sophia, Veit Bücklein, Viktoria Blumenberg, et al.. (2025). Prognostic significance of immune reconstitution following CD19 CAR T‐cell therapy for relapsed/refractory B‐cell lymphoma. HemaSphere. 9(1). e70062–e70062. 6 indexed citations

Holtermann, Anne, Martin K. Angele, Marion Subklewe, et al.. (2024). Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors. BioDrugs. 38(5). 611–637. 8 indexed citations

Laubach, Markus, Alexander Klein, Michael von Bergwelt‐Baildon, et al.. (2024). Clinical challenges in prostate cancer management: Metastatic bone-tropism and the role of circulating tumor cells. Cancer Letters. 606. 217310–217310. 2 indexed citations

Michl, Marlies, Frederick Klauschen, Thomas Kirchner, et al.. (2024). Identification of a gene expression signature associated with brain metastasis in colorectal cancer. Clinical & Translational Oncology. 26(8). 1886–1895. 3 indexed citations

Stock, Sophia, Adrian Gottschlich, Janina Dörr, et al.. (2024). Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma. Cancer Immunology Immunotherapy. 73(6). 100–100. 2 indexed citations

10.

Lange, Philipp, Dorit Di Gioia, M. Schmidt, et al.. (2023). Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience. Journal of Cancer Research and Clinical Oncology. 149(15). 13973–13983. 3 indexed citations

11.

Rausch, Christian, Maja Rothenberg‐Thurley, Annika Dufour, et al.. (2023). Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 37(6). 1234–1244. 45 indexed citations

12.

Stemmler, Hans‐Joachim, Fabian Hauck, Hendrik Schulze‐Koops, et al.. (2022). sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study. Blood Advances. 7(5). 832–844. 11 indexed citations

13.

Reischer, Anna, Stephan Krüger, & Michael von Bergwelt‐Baildon. (2021). Checkpoint-Inhibitoren – aktuelle Versorgungsstandards und Zukunftstrends. DMW - Deutsche Medizinische Wochenschrift. 146(17). 1108–1118.

14.

Wennhold, Kerstin, Martin Thelen, María A. García-Márquez, et al.. (2021). CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses. Cancer Immunology Research. 9(9). 1098–1108. 65 indexed citations

15.

Kochanek, Matthias, Alexander Shimabukuro‐Vornhagen, Gernot Beutel, et al.. (2019). Prävalenz von Krebspatienten auf deutschen Intensivstationen. Medizinische Klinik - Intensivmedizin und Notfallmedizin. 115(4). 312–319. 8 indexed citations

16.

Wennhold, Kerstin, Martin Thelen, Hans Schlößer, et al.. (2017). Using Antigen-Specific B Cells to Combine Antibody and T Cell–Based Cancer Immunotherapy. Cancer Immunology Research. 5(9). 730–743. 28 indexed citations

17.

Platten, Martin, Norma Jung, Susanna Trapp, et al.. (2016). Cytokine and Chemokine Signature in Elite Versus Viremic Controllers Infected with HIV. AIDS Research and Human Retroviruses. 32(6). 579–587. 13 indexed citations

18.

Müller, Philipp, Matthias Kreuzaler, Tarik A. Khan, et al.. (2015). Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine. 7(315). 315ra188–315ra188. 269 indexed citations

19.

Müller, Philipp, Kea Martin, Sebastian Theurich, et al.. (2014). Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research. 2(8). 741–755. 150 indexed citations

20.

Rabenhorst, Anja, Max Schlaak, Lukas C. Heukamp, et al.. (2012). Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 120(10). 2042–2054. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact